Last reviewed · How we verify
HX575 recombinant human erythropoietin alfa
HX575 recombinant human erythropoietin alfa is a Small molecule drug developed by Sandoz. It is currently FDA-approved. Also known as: HX575 epoetin alfa.
HX575, a recombinant human erythropoietin alfa marketed by Sandoz, holds a significant position in the treatment of anemia. The drug's key strength lies in its established market presence, supported by a key composition patent expiring in 2028. The primary risk to HX575 is the potential increase in competition as the patent expiration approaches.
At a glance
| Generic name | HX575 recombinant human erythropoietin alfa |
|---|---|
| Also known as | HX575 epoetin alfa |
| Sponsor | Sandoz |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Impact of Erythropoietin on Hematological Adaptations and Physical Performance (PHASE4)
- Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes (PHASE3)
- Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL) (PHASE2)
- Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients (PHASE3)
- A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis (PHASE3)
- Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe) (PHASE2)
- Traumatic Optic Neuropathy Treatment Trial 2 (PHASE3)
- Effects of Erythropoietin for Cognitive Side-effects of ECT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HX575 recombinant human erythropoietin alfa CI brief — competitive landscape report
- HX575 recombinant human erythropoietin alfa updates RSS · CI watch RSS
- Sandoz portfolio CI
Frequently asked questions about HX575 recombinant human erythropoietin alfa
What is HX575 recombinant human erythropoietin alfa?
Who makes HX575 recombinant human erythropoietin alfa?
Is HX575 recombinant human erythropoietin alfa also known as anything else?
What development phase is HX575 recombinant human erythropoietin alfa in?
Related
- Manufacturer: Sandoz — full pipeline
- Also known as: HX575 epoetin alfa
- Compare: HX575 recombinant human erythropoietin alfa vs similar drugs
- Pricing: HX575 recombinant human erythropoietin alfa cost, discount & access